A randomized, double-blind, phase III, non-inferiority clinical trial comparing the efficacy and safety of TA4415V (a proposed Trastuzumab biosimilar) and Herceptin (Trastuzumab reference product) in HER2-positive early-stage breast Cancer patients

Peer Review reports

Original Submission
20 Dec 2021	Submitted	Original manuscript
11 Jan 2022	Reviewed	Reviewer Report
16 Mar 2022	Reviewed	Reviewer Report
20 Apr 2022	Author responded	Author comments - Farhad Shahi
27 Jun 2022	Reviewed	Reviewer Report
13 Jul 2022	Author responded	Author comments - Farhad Shahi
Resubmission - Version 2
20 Apr 2022	Submitted	Manuscript version 2
Publishing
19 Jul 2022	Editorially accepted
28 Jul 2022	Article published	10.1186/s40360-022-00599-x

Back to article page